Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
22 23 Next >
News headline image
Why is Bluebird Bio (BLUE) Stock Down 9% Today? ↗
Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning! 
Via InvestorPlace
News headline image
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
News headline image
2 Risky Stocks That Could Soar in 2023 ↗
These "exciting" companies aren't for everyone. 
Via The Motley Fool
Looking Into bluebird bio's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analyst Ratings for bluebird bio ↗
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: 
Via Benzinga
News headline image
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
News headline image
2 Stocks That Could Double Your Money in 2023 ↗
These biotechs could crush the market, but there is more to the story. 
Via The Motley Fool
News headline image
bluebird bio Sells Second Priority Review Voucher for $95 Million
From bluebird bio, Inc.
Via Business Wire
News headline image
Newly Approved Drugs In US Command Over $200,000 On An Average ↗
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. 
Via Benzinga
News headline image
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
From bluebird bio, Inc.
Via Business Wire
News headline image
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
News headline image
After Doubling in the Past 6 Months, Is This Stock a Buy? ↗
This company has had a solid year, but there is still plenty of work ahead. 
Via The Motley Fool
News headline image
FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol ↗
 
Via Benzinga
News headline image
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment ↗
In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment. 
Via InvestorPlace
News headline image
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
From bluebird bio, Inc.
Via Business Wire
News headline image
Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting ↗
 
Via Benzinga
News headline image
Why Bluebird Bio Stock Crushed the Market Today ↗
The company looks set to continue its good momentum in the early part of next year. 
Via The Motley Fool
News headline image
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
From bluebird bio inc.
Via Business Wire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
News headline image
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga 
Via News Direct
News headline image
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
News headline image
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position ↗
 
Via Benzinga
News headline image
bluebird bio Sells Priority Review Voucher for $102 Million
From bluebird bio, Inc.
Via Business Wire
News headline image
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗
 
Via Benzinga
News headline image
Where Will Editas Medicine Be in 1 Year? ↗
The company could continue lagging the market for a while. 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Double in 2023 ↗
Both are lagging the market this year. 
Via The Motley Fool
News headline image
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.